Share |
 Article not rated yet 

Evidence based Pediatrics

Bronchodilators in bronchiolitis: should we reassess their selective use?

Authors:

Ochoa Sangrador Ca, Gimeno Díaz de Atauri Áb

aServicio de Pediatría. Complejo Asistencial de Zamora. Zamora. España.
bServicio de Pediatría. Hospital Universitario 12 de Octubre. Madrid. España.

Correspondence: C Ochoa. Email: cochoas2@gmail.com

Reference of this article.:

Ochoa Sangrador C, Gimeno Díaz de Atauri Á. Broncodilatadores en bronquiolitis: ¿debemos replantearnos su uso selectivo?. Rev Pediatr Aten Primaria. 2021;23:317-20.

Published in Internet: 20/09/2021

Abstract:

Authors’ conclusions: compared to guidelines‐guided strategy, treating infants with viral bronchiolitis using the phenotypic‐guided bronchodilator therapy strategy is a more cost‐effective strategy, because it involves a lower probability of hospital admission at lower total treatment costs. Randomized controlled trials using biomarkers to stratify patients most likely to respond to bronchodilators are necessary.

Reviewers’ commentary: the available information does not seem sufficient to make changes to the current recommendations in acute bronchiolitis management. There is still need for a predictive model that allows to identify potential responders to bronchodilators, as well as a clinical trial with a sufficient sample size to estimate the effectiveness of the strategy of its selective use.

Keywords: Costs and cost analysis.. Bronchodilators. Bronchiolitis.


 


Comments

This article has no comments yet.

ISSN 2174-4106  Publicación Open Acess, incluida en DOAJ, sin cargo por publicación.

Privacy Policy | Web map | Copyright 2022 Lúa Ediciones 3.0 | Contact